Sabra Health Care REIT, Inc. (SBRA)
Gear Up for Sabra (SBRA) Q4 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Sabra (SBRA), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
Sabra Health Care REIT: Buy Into Future Demand For Skilled Nursing Facilities
Sabra Health Care REIT gets rated buy, agreeing with consensus, and driven heavily by macro-level demand forecasts for skilled nursing facilities. The stock is undervalued on forward P/FFO vs key peers, and is trading close to its moving average now. The firm has investment-grade ratings from Fitch and Moody's agencies.
Sabra Health Care REIT: A High-Yielding Gift Just In Time For The New Year
With the FED's rate cut predictions for 2025, Sabra Health Care REIT offers a buying opportunity for long-term investors, especially retirees and income investors. Sabra's solid fundamentals, including improved occupancy rates and a safe 6% dividend yield, make it an attractive investment despite recent market sell-offs. The REIT's balance sheet has strengthened, with Moody's upgrading their outlook to positive, indicating potential for future investment opportunities and price appreciation.
Sabra (SBRA) Upgraded to Buy: Here's Why
Sabra (SBRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sabra Health Care REIT: A Promising Value Play In Healthcare Real Estate
Sabra Health Care REIT offers a compelling investment opportunity with a reasonable valuation, trading at 13.6x 2024 FFO and 12.9x 2025 FFO. The company benefits from strong industry fundamentals, including an aging population and growing demand for senior living and healthcare facilities. Q3'24 results showed robust performance with occupancy gains and NOI growth, particularly in the SHOP portfolio, indicating effective operational leverage.
Sabra Health Care REIT, Inc. (SBRA) Q3 2024 Earnings Call Transcript
Sabra Health Care REIT, Inc. (NASDAQ:SBRA ) Q3 2024 Earnings Conference Call November 1, 2024 1:00 PM ET Company Participants Lukas Hartwich - Senior Vice President, Finance Rick Matros - Chief Executive Officer, President & Chair of the Board Talya Nevo-Hacohen - Chief Investment Officer, Treasurer & Executive Vice President Michael Costa - Chief Financial Officer Conference Call Participants Elmer Chang - Scotiabank John Kilichowski - Wells Fargo Austin Wurschmidt - KeyBanc Juan Sanabria - BMO Capital Michael Griffin - Citi Rich Anderson - Wedbush Alec Feygin - Baird Michael Stroyeck - Green Street Omotayo Okusanya - Deutsche Bank Operator Good day, everyone. My name is Adam, and I will be your conference operator today.
Sabra (SBRA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Sabra (SBRA) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Sabra Healthcare (SBRA) Q3 FFO and Revenues Surpass Estimates
Sabra Healthcare (SBRA) came out with quarterly funds from operations (FFO) of $0.37 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to FFO of $0.34 per share a year ago.
Sabra Health Care REIT: Turning The Corner
Sabra Healthcare REIT is showing a strong turnaround with impressive Q2 earnings, driven by increased occupancy and NOI growth, particularly in senior housing. The REIT's deleveraging efforts and strong liquidity position it well for future investments, with no debt maturing before 2026 and investment-grade ratings. Dividend growth is expected to resume in 2025, with management raising AFFO guidance, suggesting potential for share price appreciation despite lagging peers.
Sabra Health Care REIT, Inc. (SBRA) Q2 2024 Earnings Call Transcript
Sabra Health Care REIT, Inc. (NASDAQ:SBRA ) Q2 2024 Earnings Conference Call August 8, 2024 1:00 PM ET Company Participants Lukas Hartwich - Senior Vice President, Finance Rick Matros - Chief Executive Officer, President & Chair of the Board Talya Nevo-Hacohen - Chief Investment Officer, Treasurer & Executive Vice President Michael Costa - Chief Financial Officer Conference Call Participants Elmer Chang - Scotiabank Austin Wurschmidt - KeyBanc Capital Markets Joshua Dennerlein - Bank of America Michael Griffin - Citigroup Vikram Malhotra - Mizuho Securities John Pawlowski - Wells Fargo Rich Anderson - Wedbush Securities Michael Stroyeck - Green Street Advisors, LLC Alec Feygin - Baird Equity Research Operator Good day, everyone. My name is Christina, and I will be your conference operator today.
Sabra (SBRA) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Sabra (SBRA) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Sabra Healthcare (SBRA) Q2 FFO and Revenues Top Estimates
Sabra Healthcare (SBRA) came out with quarterly funds from operations (FFO) of $0.36 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to FFO of $0.34 per share a year ago.
